Lumasiran (sodium)
Product Specifications
UNSPSC Description
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) [1][2].
Target Antigen
Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/lumasiran-sodium.html
Purity
95.37
Solubility
10 mM in H2O
Smiles
[Lumasiran (sodium)]
Molecular Weight
17307.71
References & Citations
[1]Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282.|[2]Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 1;384(13):1216-1226.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen, away from moisture)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-132613/Lumasiran-sodium-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-132613/Lumasiran-sodium-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
1834612-06-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7094922 Inquire
Recombinant Mouse TLC domain-containing protein 2 (Tlcd2), partial
Ask
View Details